Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial

Annals of Oncology

Volumn 11, Issue 1, 2000, Pages 69-72

  Sarris, A H ^a   Hagemeister, F ^a   Romaguera, J ^a   Rodriguez, M A ^a   McLaughlin, P ^a   Tsimberidou, A M ^a   Medeiros, L J ^a   Samuels, B ^a   Pate, O ^a   Oholendt, M ^a   Kantarjian, H ^a   Burge, C ^b   Cabanillas, F ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Inex Pharmaceuticals   (Canada)

Author keywords

Liposomal vincristine; Lymphoma; Relapsed

Indexed keywords

DRUG VEHICLE; LIPOSOME; PACLITAXEL; PLATINUM; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033973456     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008348010437     Document Type: Article

References (13)

1. Carbone PP, Bono V, Frei El et al. Clinical studies with vincristine. Blood 1963; 21: 640-7.
2. Owellen RJ, Owens AH Jr, Donigian DW. The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Communical 1972; 47: 685-91.
3. Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983; 1: 146-53.
4. Longo DL, Young RC, Wesley M et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295-306.
5. Longo DL, Duffey PL, DcVita VT Jr et al. Treatment of advanced-stage Hodgkin's disease: Alternating noncrossresistant MOPP/ CABS is not superior to MOPP. J Clin Oncol 1991; 9: 1409-20.
6. Haim N, Epelbaum R, Ben-Shahar M et al. Full dose vincristine (without 2 mg dose limit) in the treatment of lymphomas. Cancer 19941; 73: 2515-9.
7. Jackson DV Jr, Paschold EH, Spurr CL et al. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer 1984; 53: 2601-6.
8. Kanter PM, Klaich GM, Bullard GA et al. Liposome encapsulated vincristine: Preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs (see comments). Anti-Cancer Drugs 1994; 5: 579-90.
9. Mayer LD, Nayar R, Thies RL et al. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 1993; 33: 17-24.
10. Boman NL, Masin D, Mayer LD et al. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 1994; 54: 2830-3.
11. Gelmon KA, Tolcher A, Diab AR et al. Phase I study of liposomal vincristine. J Clin Oncol 1999; 17: 697-705.
12. Harris NL, Jaffe ES, Stein H et al. A Revised European American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
13. 13. Rodriguez MA, Cabanillas FC, Velasquez W et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-41.